Welcome to our dedicated page for Avricore Health SEC filings (Ticker: AVCRF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Avricore Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Avricore Health's regulatory disclosures and financial reporting.
Avricore Health Inc., a foreign private issuer based in Vancouver, submitted a report listing multiple disclosures for the period around March 31, 2026. The company furnished an interim financial statements report for March 31, 2026 and a related interim MD&A for March 31, 2026, together with CEO and CFO certifications of those interim filings dated June 1, 2026.
The report also includes a news release titled “Avricore Health Closes $1.254 Million Financing” dated June 17, 2026, and a Canadian Form 45-106F1 Report of Exempt Distribution dated June 23, 2026. Extensive instructions are provided on how issuers or underwriters must file exempt distribution reports across Canadian jurisdictions, including use of specific security type codes and disclosure of confidential purchaser and control person information.
Avricore Health Inc. filed a Form 6-K as a foreign private issuer for January 2026. The filing primarily furnishes a news release titled “HealthTab to Expand Across North East London,” indicating the company is highlighting expansion activity related to its HealthTab platform in that region.
Avricore Health Inc. submitted a Form 6-K as a foreign private issuer for November 2025. The filing mainly furnishes a news release titled “HealthTab to Power NHS Pilot”, listed as Exhibit 1 and dated November 27, 2025. The report is signed on behalf of the company by Chief Financial Officer Kiki Smith on December 10, 2025, confirming the news release as official company communication.